State-of-the-Art Webinar Series in Cardiovascular Disease 2011
Presented by The American Heart Association's Functional Genomics and Translational Biology Council and Circulation Cardiovascular Genetics
The State of the Art Webinar Series 2011 provides critical insight into why genetics, genomics and translational biology are important in clinical and basic science. Webinars will be presented quarterly starting with Jan. 21, 2011, and continuing April, July and October.
After completing this series of webinars, participants will be able to:
- Discuss the potential of pharmacogenomics in the management of cardiovascular disease.
- Describe the role of epigenetics in cardiovascular disease and the implications for clinical practice.
- Discuss current technology used to sequence DNA and genomes and the implications for clinical practice.
- Describe the role of miRNA in cardiovascular and vascular disease.
Plasma Lipids and Risk for Myocardial Infarction
Sekar Kathiresan, M.D.
Assistant Professor of Medicine
Harvard Medical School
Director, Preventive Cardiology
Massachusetts General Hospital
Presented by: Dan Roden, M.D.
Assistant Vice - Chancellor for Personalized Medicine
Vanderbilt University School of Medicine
After participating in this activity, participants will be able to:
1. Describe the role of genetically-determined drug metabolism in drug response
2. Recognize drug responses in which genetic variation may play a role
3. Recognize the way in which rare and common genetic variants influence drug response